PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmiLibertas AcademicaJournal Home
 
Biomark Insights. 2012; 7: 71–79.
Published online Jun 25, 2012. doi:  10.4137/BMI.S9873
PMCID: PMC3394595
Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury
J. Susie Zoltewicz,1 Dancia Scharf,2 Boxuan Yang,1 Aarti Chawla,3 Kimberly J. Newsom,1 and Lijuan Fang1
1Banyan Biomarkers Inc., Alachua, Florida, USA
2Banyan Biomarkers Inc., West Lafayette, Indiana, USA
3Banyan Biomarkers Inc., Carlsbad, California, USA
Corresponding author email: szoltewicz/at/banyanbio.com
Abstract
After traumatic brain injury (TBI), glial fibrillary acidic protein (GFAP) and other brain-derived proteins and their breakdown products are released into biofluids such as CSF and blood. Recently, a sandwich ELISA was constructed that measured GFAP concentrations in CSF or serum from human mild-moderate TBI patients. The goals of the present study were to characterize the same two antibodies used in this ELISA, and to determine which GFAP bands are detected by this antibody combination. Here, both antibodies recognized GFAP specifically in human brain and post-TBI CSF in a cluster of bands ranging from 50–38 kDa, that resembled bands from calpain-cleaved GFAP. By immunoprecipitation, the anti-GFAP Capture antibody recovered full length GFAP and its breakdown products from human brain lysate and post-TBI CSF. These findings demonstrate that the anti-GFAP ELISA antibodies non-preferentially detect intact GFAP and GFAP breakdown products, underscoring their utility for detecting brain injury in human patients.
Keywords: GFAP, GFAP-BDP, traumatic brain injury, human
Articles from Biomarker Insights are provided here courtesy of
Libertas Academica